{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:49:51Z","timestamp":1782236991739,"version":"3.54.5"},"reference-count":23,"publisher":"BMJ","funder":[{"DOI":"10.13039\/100017521","name":"Esteve Pharmaceuticals","doi-asserted-by":"publisher","award":["Award number: 99551"],"award-info":[{"award-number":["Award number: 99551"]}],"id":[{"id":"10.13039\/100017521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2026,5,26]]},"DOI":"10.1136\/ejhpharm-2025-004912","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:20:59Z","timestamp":1782235259000},"page":"ejhpharm-2025-004912","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Extended physicochemical stability of ready-to-administer fosnetupitant\/palonosetron infusion solutions and admixtures with dexamethasone injection"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1433-0128","authenticated-orcid":false,"given":"Zoe","family":"Mittmann","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kraemer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"2026062310203068000_ejhpharm-2025-004912v1.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.2","article-title":"2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents","volume":"32","author":"Herrstedt","year":"2023","journal-title":"Support Care Cancer"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.3","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02474-5"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.4","unstructured":"European Medicines Agency . Akynzeo: summary of product characteristics. 2015. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/akynzeo-epar-product-information_en.pdf[Accessed03 Dec 2025]."},{"key":"2026062310203068000_ejhpharm-2025-004912v1.5","unstructured":"Tyler T , Venturini A , Roeland E , et al . Stability and compatibility of the combination of intravenous (IV) NE PA (fosnetupitant-palonosetron) solution and dexamethasone (DEX) for efficient IV administration of antiemetic prophylaxis [Poster presentation]. American Society of Health-System Pharmacists (ASHP) Midyear Clinical Virtual Meeting, 6\u201310 December 2020."},{"key":"2026062310203068000_ejhpharm-2025-004912v1.6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/0018578719888912","article-title":"Physical and Chemical Stability of Dexamethasone Sodium Phosphate in Intravenous Admixtures Used to Prevent Chemotherapy-Induced Nausea and Vomiting","volume":"56","author":"Buga","year":"2021","journal-title":"Hosp Pharm"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.7","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D509"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.8","first-page":"398","article-title":"Compatibility and stability of aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate","volume":"8","author":"Trissel","year":"2004","journal-title":"Int J Pharm Compd"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.9","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2016-000980"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.10","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) . Harmonized tripartite guidelines for validation of analytical procedures: text and methodology q2(r2). 2024. Available: https:\/\/www.ema.europa.eu\/en\/ich-q2r2-validation-analytical-procedures-scientific-guideline"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.11","doi-asserted-by":"crossref","first-page":"20220002","DOI":"10.1515\/pthp-2022-0002","article-title":"Y-site compatibility of intravenous medications commonly used in intensive care units: laboratory tests on 75 mixtures involving nine main drugs","volume":"7","author":"Ayari","year":"2022","journal-title":"Pharm Technol Hosp Pharm"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.12","unstructured":"NHS Pharmaceutical Quality Assurance Committee . A Standard Protocol for Deriving and Assessment of Stability. Part 1 \u2013 Aseptic Preparations (Small Molecules). 2019. Available: https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2013\/12\/Stability-part-1-small-molecules-5th-Ed-Sept-19.pdf[accessed3 Dec 2025]"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.13","unstructured":"Helsinn Birex Pharmaceuticals Ltd . Akynzeo\u00ae 235 mg\/0.25 mg konzentrat zur herstellung einer infusionsl\u00f6sung. 2020. Available: https:\/\/www.esteve.com\/de\/produkte\/detail\/akynzeo[Accessed10 Dec 2025]."},{"key":"2026062310203068000_ejhpharm-2025-004912v1.14","unstructured":"Food and Drug Administration . Akynzeo \u2013 prescribing information, 2023. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/210493Orig1s005lbl.pdf[Accessed03 Dec 2025]."},{"key":"2026062310203068000_ejhpharm-2025-004912v1.15","first-page":"317","article-title":"A novel validated RP-HPLC-DAD method for the simultaneous estimation of Netupitant and Palonosetron in bulk and pharmaceutical dosage form with forced degradation studies","volume":"8","author":"Panigrahy","year":"2015","journal-title":"Int J ChemTech Res"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.54037\/WJPS.2022.100112","article-title":"Stability Indicating Method Development and Validation for Simultaneous Estimation of the Netupitant and Palonosetron in Bulk and Pharmaceutical Dosage Form by RP-HPLC","volume":"10","author":"Gandla","year":"2022","journal-title":"World J Pharm Sci"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.17","doi-asserted-by":"crossref","unstructured":"Surendra P , Sreenivasa Prasanna P , Thejomoorthy K . Development and Validation of New Analytical Method for The Simultaneous Estimation of Netupitant And Palonosetron In Pharmaceutical Dosage Form. Int J Pharm Chem 2021;50\u20139. doi:10.46796\/ijpc.vi.158","DOI":"10.46796\/ijpc.vi.158"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.18","first-page":"463","article-title":"Development and validation of RP-HPLC method for simultaneous estimation of Netupitant and Palonosetron in pharmaceutical dosage form","volume":"6","author":"Tejakshi","year":"2019","journal-title":"Eur J Biomed Pharm Sci"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.19","first-page":"101","article-title":"A Photo Stability Indicating HPLC technique for Validation of Netupitant and Palonosetron in Bulk and Formulations","volume":"1","author":"Salomi","year":"2020","journal-title":"Int J Res Pharm Chem Anal"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.20","first-page":"1129","article-title":"RP-HPLC method development and validation for the simultaneous estimation of fosnetupitant and palonosetron in bulk and combined formulation","volume":"9","author":"Kousar","year":"2020","journal-title":"World J Pharm Res"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.21","first-page":"419","article-title":"Development and validation of stability-indicating HPLC method for simultaneous determination of fosnetupitant and palonosetron in pharmaceutical dosage form","volume":"7","author":"Suman","year":"2020","journal-title":"Eur J Biomed"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00764-020-00014-3","article-title":"Butyl-based reversed-phase high-performance liquid chromatography and silica normal-phase high-performance thin-layer chromatography methods for the determination of palonosetron in the presence of degradation products and dosage form additives","volume":"33","author":"Tantawy","year":"2020","journal-title":"JPC-Journal of Planar Chromatography"},{"key":"2026062310203068000_ejhpharm-2025-004912v1.23","doi-asserted-by":"crossref","unstructured":"Hossain MM . Studies of stress degradation and impurity profiles of some 5-HT3 antagonists [Doctoral dissertation]. University of Dhaka, 2019 doi:10.3329\/dujps.v17i1.37113","DOI":"10.3329\/dujps.v17i1.37113"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2025-004912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:21:10Z","timestamp":1782235270000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2025-004912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":23,"alternative-id":["10.1136\/ejhpharm-2025-004912"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2025-004912","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}